Clinical”[Mesh] OR “Pharmacokinetics”[Mesh] OR “Drug Interactions”[Mesh] “Dose-Response Relationship, Drug”[Mesh] OR Pharmaco*[tiab] OR exposure*[tiab] OR drug monitoring[tiab] OR drug concentration*[tiab] OR target concentration*[tiab]...
. Dilute Soliris to a final concentration of 5 mg/mL by adding the appropriate amount (equal volume of diluent to drug volume) of 0.9% Sodium Chloride Injection, USP; 0.45% Sodium Chloride Injection, USP; 5% Dextrose in Water Injection, USP; or Ringer’s Injection, USP to the infusion b...
Fig. 14. Case #2: Serum creatinine concentration (A) and liquid biopsy (circulating donor-derived cell-free DNA, dd-cfDNA) results (B) over time. 5. Discussion This is the first experience with the combined use of eculizumab and obinutuzumab in the setting of ABMR. In both the highly se...
Change in free C5 concentration over time was also assessed. Safety Adverse events were recorded by type, incidence, and severity. Antidrug antibodies were also assessed. A safety review committee monitored safety, and an independent data monitoring committee monitored data for cases of meningococcal ...
Infusion stability was assessed in SB12 samples (diluted in 0.9% NaCl, 0.45% NaCl, and 5% dextrose, final concentration of 5 mg/mL per clinical trial protocol and the reference product's label) kept at 5 ± 3 °C for up to 3 months, then 30 ± 2 °C/65 ± 5% relative humidity ...
Dilute BKEMV to a final concentration of 5 mg/mL by adding the appropriate amount (equal volume of diluent to drug volume) of 0.9% Sodium Chloride Injection, USP; 0.45% Sodium Chloride Injection, USP; 5% Dextrose in Water Injection, USP; or Ringer’s Injection, USP to the infusio...